Kvetiapin Accord

Quetiapine, the active ingredient in Kvetiapin Accord, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the management of schizophrenia, bipolar disorder (both manic and depressive phases), and as an adjunctive therapy for major depressive disorder in adult patients.

GNH USA supplies Kvetiapin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to global healthcare providers.

Quetiapine is used in psychiatric disorders that involve dysregulation of dopamine and serotonin pathways.

- Schizophrenia: reduces psychotic symptoms such as hallucinations, delusions, and thought disorder. - Bipolar disorder (manic episodes): stabilizes mood and decreases mania severity. - Bipolar disorder (depressive episodes): alleviates depressive symptoms and improves functional outcomes. - Major depressive disorder (adjunct): enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Agranulocytosis (rare)

When prescribing quetiapine, clinicians should consider several safety considerations to minimise risk.

- Cardiovascular monitoring: assess blood pressure and heart rate, especially in patients with orthostatic risk. - Metabolic assessment: monitor weight, fasting glucose, and lipid profile regularly. - CNS effects: caution in patients prone to sedation or with a history of falls. - Psychiatric evaluation: watch for emergence or worsening of suicidal thoughts, particularly early in therapy. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetric specialist. - Store at ambient temperature below 25 °C: keep in original container, protect from moisture and light.

Quetiapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): increase quetiapine levels. - Strong CYP3A4 inducers (rifampin, carbamazepine): decrease quetiapine levels. - CNS depressants (alcohol, benzodiazepines): enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Other antipsychotics or dopamine antagonists: raise risk of extrapyramidal symptoms. - Antidepressants (SSRIs, SNRIs): may increase serotonergic side effects. - QT‑prolonging agents: combined use may raise arrhythmia risk.